Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to TARSA's First Quarter 2026 Financial Results Conference Call. As a reminder, this call is being recorded and all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. At this time, I would like to turn the call over to David Nakasone, Head of Miscellations, to lead off the call. David, you may begin. Thank you. Before we begin, I encourage everyone to visit the investor section of the TARCIS website to view the earnings release and related materials we will be discussing today. Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Matawala, our Chief Commercial Officer, and Jeff Farrell, our Chief Financial Officer and Chief Strategy Officer. I'd like to draw your attention to slide three, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details. With that, I'll turn the call over to Bobby. Good afternoon, and thank you for joining us. We are off to a strong start in 2026. with a quarter that reflects the continued momentum of Xtembe's launch and the strength of our key growth drivers. We've always believed Xtembe would be revolutionary, and our strong first quarter results reflect that. Every key metric we track, including the number of riders, depth of prescribing, awareness and evidence generation, continue to grow substantially quarter over quarter. These are the same drivers we have committed to delivering on,...